Latest Breaking News On - Why avenue therapeutics - Page 1 : vimarsana.com

FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to $450.9M by 2027.

Pharmaceuticals inc xforxolremdiWhy avenue therapeuticsStock is fallingRare pediatric disease priority review voucherBrookline capital marketsGoing on with sofi technologies stock